331 related articles for article (PubMed ID: 34288538)
1. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.
Yoon SM; Luterstein E; Chu FI; Cao M; Lamb J; Agazaryan N; Low D; Raldow A; Steinberg ML; Lee P
Cancer Med; 2021 Sep; 10(17):5897-5906. PubMed ID: 34288538
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen.
Henke L; Kashani R; Robinson C; Curcuru A; DeWees T; Bradley J; Green O; Michalski J; Mutic S; Parikh P; Olsen J
Radiother Oncol; 2018 Mar; 126(3):519-526. PubMed ID: 29277446
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
[TBL] [Abstract][Full Text] [Related]
4. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma.
Webking S; Sandoval ML; Chuong MD; Ucar A; Aparo S; De Zarraga F; Sahin I; Biachi T; Kim DW; Hoffe SE; Frakes JM; Palm RF
Cancer Control; 2023; 30():10732748231219069. PubMed ID: 38038261
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer.
Henke LE; Stanley JA; Robinson C; Srivastava A; Contreras JA; Curcuru A; Green OL; Massad LS; Kuroki L; Fuh K; Hagemann A; Mutch D; McCourt C; Thaker P; Powell M; Markovina S; Grigsby PW; Schwarz JK; Chundury A
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):379-389. PubMed ID: 34474109
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience.
Smile TD; Reddy CA; Qiao-Guan G; Winter WI; Stephans KL; Woody NM; Balagamwala EH; Amarnath SR; Magnelli A; AlHilli MM; Michener CM; Mahdi H; DeBernardo RL; Rose PG; Cherian SS
J Radiosurg SBRT; 2021; 7(3):189-197. PubMed ID: 33898082
[TBL] [Abstract][Full Text] [Related]
7. SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes.
Regnery S; Buchele C; Piskorski L; Weykamp F; Held T; Eichkorn T; Rippke C; Katharina Renkamp C; Klüter S; Ristau J; König L; Koerber SA; Adeberg S; Debus J; Hörner-Rieber J
Radiother Oncol; 2022 Mar; 168():106-112. PubMed ID: 35121031
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes.
Weykamp F; Herder-Wagner C; Regnery S; Hoegen P; Renkamp CK; Liermann J; Rippke C; Koerber SA; König L; Buchele C; Klüter S; Debus J; Hörner-Rieber J
Strahlenther Onkol; 2022 Jan; 198(1):56-65. PubMed ID: 34468783
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Front Oncol; 2022; 12():842402. PubMed ID: 35356227
[TBL] [Abstract][Full Text] [Related]
10. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
11. Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer.
Chuong MD; Bryant J; Mittauer KE; Hall M; Kotecha R; Alvarez D; Romaguera T; Rubens M; Adamson S; Godley A; Mishra V; Luciani G; Gutierrez AN
Pract Radiat Oncol; 2021; 11(2):134-147. PubMed ID: 32947042
[TBL] [Abstract][Full Text] [Related]
12. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
14. Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial.
van Dams R; Wu TC; Kishan AU; Raldow AC; Chu FI; Hernandez J; Cao M; Lamb JM; Mikaeilian A; Low DA; Steinberg ML; Lee P
Radiother Oncol; 2022 May; 170():14-20. PubMed ID: 34107296
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
Reshko LB; Baliga S; Crandley EF; Harry Lomas IV; Richardson MK; Spencer K; Bennion N; Mikdachi HE; Irvin W; Kersh CR
Gynecol Oncol; 2020 Dec; 159(3):611-617. PubMed ID: 33059914
[TBL] [Abstract][Full Text] [Related]
17. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
18. REPeated mAgnetic resonance Image-guided stereotactic body Radiotherapy (MRIg-reSBRT) for oligometastatic patients: REPAIR, a mono-institutional retrospective study.
Chiloiro G; Panza G; Boldrini L; Romano A; Placidi L; Nardini M; Galetto M; Votta C; Campitelli M; Cellini F; Massaccesi M; Gambacorta MA
Radiat Oncol; 2024 Apr; 19(1):52. PubMed ID: 38671526
[TBL] [Abstract][Full Text] [Related]
19. Overall and chemotherapy-free survival following stereotactic body radiation therapy for abdominopelvic oligometastases.
Shahi J; Peng J; Donovan E; Vansantvoort J; Wong R; Tsakiridis T; Quan K; Parpia S; Swaminath A
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):563-569. PubMed ID: 32497405
[TBL] [Abstract][Full Text] [Related]
20. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
